Displaying 97 - 108 of 149
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Displaying 97 - 108 of 149